WHO ICTRP trial
A Phase 2 Study of LY573636 as Treatment for Patients with Platinum-Resistant…
EUCTR2006-005971-17-IT · EU Clinical Trials Register · Not Recruiting
Key facts
| Trial ID | EUCTR2006-005971-17-IT |
|---|---|
| Public title | A Phase 2 Study of LY573636 as Treatment for Patients with Platinum-Resistant Ovarian Cancer Protocol H8K-MC-JZAG - ND |
| Scientific title | A Phase 2 Study of LY573636 as Treatment for Patients with Platinum-Resistant Ovarian Cancer Protocol H8K-MC-JZAG - ND |
| Primary sponsor | ELI LILLY |
| Registry | EU Clinical Trials Register |
| Recruitment status | Not Recruiting |
| Study type | Interventional clinical trial of medicinal product |
| Countries | Italy |
| Conditions | patients with epithelial ovarian cancer who have received no more than 2 prior systemic treatment regimens for platinum-resistant disease. MedDRA version: 6.1 Level: PT Classification code 10061328 |
| Interventions | Product Name: LY573636 Pharmaceutical Form: Powder for infusion* CAS Number: 519055-63-1 Current Sponsor code: LY573636 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 500- |
| Registration date | May 16, 2007 |
| Target size | 50 |
| Secondary IDs | H8K-MC-JZAG |
| Registry page | clinicaltrialsregister.eu |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: